Gastrointestinal stromal tumors (GISTs) predominantly harbor activating mutations in the receptor tyrosine kinase KIT. To genetically dissect in vivo the requirement of different signal transduction pathways emanating from KIT for tumorigenesis, the oncogenic Kit V558Δ mutation was combined with point mutations abrogating specific phosphorylation sites on KIT. Compared with single-mutant Kit V558Δ/+ mice, double-mutant Kit V558Δ;Y567F/Y567F knock-in mice lacking the SRC family kinase-binding site on KIT (pY567) exhibited attenuated MAPK signaling and tumor growth. Surprisingly, abrogation of the PI3K-binding site (pY719) in Kit V558Δ;Y719F/Y719F mice prevented GIST development, although the interstitial cells of Cajal (ICC), the cells of origin of GIST, were normal. Pharmacologic inhibition of the PI3K pathway in tumor-bearing Kit V558Δ/+ mice with the dual PI3K/ mTOR inhibitor voxtalisib, the pan-PI3K inhibitor pilaralisib, and the PI3K-alpha-restricted inhibitor alpelisib each diminished tumor proliferation. The addition of the MEK inhibitor PD-325901 or binimetinib further decreased downstream KIT signaling. Moreover, combining PI3K and MEK inhibition was effective against imatinibresistant Kit V558Δ;T669I/+ tumors.
T argeted therapies have revolutionized cancer care, but the rapidity with which resistance to single-agent treatments develops has unsettled the field. Often the mechanism of resistance is further mutation of the originally targeted oncogene, as occurs with ABL1 T315I , KIT T670I , EGFR T790M , and ALK L1196M . Thus, key protumorigenic signals must be emanating from these "oncogenic drivers." To date, however, the contribution of individual signal transduction sites on oncogenic drivers has not been dissected using endogenously encoded oncogenes in fully immunocompetent, genetically engineered models of cancer.
Gastrointestinal stromal tumors (GISTs) derive from mesenchymal pacemaker cells of the gastrointestinal tract known as interstitial cells of Cajal (ICCs) or their progenitors (1, 2) . The receptor tyrosine kinase KIT is essential for the development of ICCs, and KITactivating mutations are detected in the majority of GISTs (1, 3, 4) . The tyrosine kinase inhibitor imatinib mesylate is approved for firstline treatment of advanced GIST. as well as for adjuvant treatment following resection of KIT-positive GIST (5) . Despite the early clinical success of imatinib for the treatment of GIST, it is rarely curative, with the main outcome being partial response or stable disease, requiring lifelong therapy (6) . In addition, imatinib resistance frequently arises from second-site mutations in Kit (7, 8) .
We previously generated a mouse model of GIST that carries the Kit V558Δ mutation, which is prototypical for Kit exon 11 mutations found in both spontaneous and familial GIST (9, 10) . We also engineered imatinib-resistant Kit V558Δ;T669I/+ mice that model the human "gatekeeper mutation" Kit T670I (7, 8, 11) . Both mouse models develop gastric and colonic ICC hyperplasia and cecal GIST by histology and aberrant activation of SRC family kinase (SFK), PI3-kinase (PI3K)/AKT/S6, STAT3, and MAPK/ ERK signal transduction pathways indistinguishable from human GIST (10) (11) (12) (13) . While these findings confirm the central and persistent role of KIT in the pathogenesis of GIST, they also highlight the need to identify other targets to improve clinical outcomes per se and provide the means to prevent or overcome the emergence of resistant clones. As aberrant KIT signaling is essential for most GISTs, we aimed to identify the proximal downstream targets critical for tumor development and/or maintenance.
Kit gain-of-function mutations are also found in neoplasms of the hematopoietic system, such as in mast cells and myeloid cells. In contrast to Kit mutations in GIST, which typically are weak gainof-function mutations, Kit gain-of-function mutations in the hematopoietic system are strong mutations typically arising in the Significance Oncogenic receptor tyrosine kinases (RTKs) are important drug targets in the clinical setting. While RTK inhibitors have become important tools in the clinic, as has been demonstrated with chronic myelogenous leukemia and gastrointestinal stromal tumors (GIST), drug resistance invariably develops. The tools and rationale for the treatment of RTK drug resistance are limited, and success is of short duration. The identification of secondary intracellular drug targets is thus of critical importance. By using new Kit-GIST mouse models in which specific Kit signaling cascades are inhibited, we show the importance of PI3 kinase signaling in tumor development, as well as the utility of PI3 kinase inhibition in the treatment of primary and imatinib-resistant GIST. These studies provide a rationale for targeting dominant molecular pathways in tumors driven by oncogenic kinases.
activation loop of the Kit kinase. This appears to be the result of the activation by KIT of a negative regulator of PI3K, SHIP1, in hematopoietic lineages. In agreement with this idea, SHIP1 loss-offunction mice display mast cell hyperplasia (14) .
The receptor tyrosine kinase KIT contains 22 cytoplasmic tyrosine phosphorylation sites that are conserved between mouse and humans. Normal and oncogenic kinase activity of KIT results in their phosphorylation and the recruitment of a multitude of signal transducers to one or more of these docking sites on KIT. Depending on the cellular context, this signal transduction process elicits various biological responses, such as cell survival, proliferation, secretion, and migration. Two phosphorylation sites have been extensively studied in the nononcogenic setting. The phospho-Y567 (pY567) site, among other signaling intermediates, interacts with the SFKs (15, 16) STAT3, and GRB2 (17) , while phospho-Y719 (pY719) is the sole site on KIT for the recruitment of PI3K family members (18, 19) .
We and others have studied the individual contributions of pY567 and pY719 to nononcogenic KIT signal transduction and, ultimately, cellular fate decisions using knock-in mouse models. Generally, KIT is essential for melanogenesis, hematopoiesis, and gametogenesis. Kit Y567F/Y567F mice specifically lacking the KIT Y567 phosphorylation site exhibit minor pigmentation changes and an age-dependent differentiation block in pro-B and pro-T cells, an erythroblast-intrinsic defect in stress erythropoiesis, but normal fertility (20) (21) (22) . In contrast, Kit Y719F/Y719F mice lacking the KIT Y719 phosphorylation site have normal pigmentation and hematopoiesis, but males are sterile and females have defective ovarian follicle maturation (20, (23) (24) (25) . Importantly, while KIT signaling is required in the ICC lineage, KIT-mediated SFK or PI3K signaling is dispensable, since both Kit Y567F/Y567F and Kit Y719F/Y719F mice show normal ICC development (4, 22, 26) .
The individual downstream KIT signaling pathways required for the oncogenic transformation of ICCs and GIST maintenance are unknown, however. Identification of vital pathways could provide additional strategies to enhance the efficacy of existing therapies or to circumvent imatinib resistance. Thus, double-knock-in mouse models were generated combining the oncogenic Kit V558Δ mutation with either the Kit Y567F or the Kit Y719F mutation in the endogenous Kit locus. Vital pathways identified with this approach were then targeted by specific inhibitors in both our imatinib-sensitive and imatinib-resistant mouse models to translate the genetic findings.
Results
PI3K, but Not SFK, Is Required for ICC Hyperplasia and GIST Oncogenesis.
To dissect the in vivo contribution of individual signal transduction pathways emanating from oncogenic KIT, we genetically abrogated the SFK-binding site pY567 or the PI3-kinase binding site pY719 in the KIT V558Δ oncoprotein by substituting the tyrosine to phenylalanine ( Fig. 1A and Fig. S1 ). Heterozygosity for the Kit V558Δ allele is sufficient to induce GIST development, while homozygosity causes perinatal lethality in mice (10) . Because KIT dimerizes, homozygous phenylalanine substitutions were necessary to abrogate signaling from the specified tyrosines. analysis revealed normal morphology of the stomach, cecum, and colon, with a normal density of ICCs in the myenteric plexus (Fig.  1C, j- mice further reduced survival despite disruption of KIT Y567 signaling, confirming that signaling from other KIT tyrosines contributed to KIT signaling in GIST (Fig. 2D ).
To verify the impaired SFK signaling in Kit V558Δ;Y567F/Y567F tumors, we performed IHC and Western blot analysis. KIT , and Kit V558Δ;Y719F/+ mice. Antibodies specific for pKIT-Y567/Y569, pKIT-Y719, and KIT were used.
STAT3 phosphorylation without altering KIT expression (Fig. 2E, a,  d , g, and j), consistent with our previous studies (11) (12) (13) . In contrast, MAPK1/3 phosphorylation was at an intermediate level in untreated Kit V558Δ;Y567F/Y567F tumors, indicating that SFK partially contributed to MAPK activation (Fig. 2E, g-i) .
Western blot analysis further confirmed similar PI3K pathway activation in untreated Kit V558Δ;Y567F/Y567F and Kit V558Δ/+ tumors, as demonstrated by phosphorylation of S6 and 4E-BP1 (Fig. 2 F  and G) . Again, phospho-MAPK1/3 (ERK1/2) was reduced in Kit V558Δ;Y567F/Y567F tumors. SFK pathway activation was greatly reduced, as expected, but phospho-STAT3 was greatly reduced as well (Fig. 2 F and G (Figs. 1C, j-l and 3 A and B) . The absence of GIST in Kit V558Δ;Y719F/Y719F mice explained their normal lifespan (Fig. 1B) . Remarkably, Kit V558Δ;Y719F/+ mice (harboring one WT Kit allele) also had a normal lifespan and did not develop GIST (Fig. 3C) mice are fertile, Kit Y719F/Y719F mice showed a distinct blockage in spermatogenesis (24) . Thus, we asked whether addition of the gain-of-function mutation Kit V558Δ to the Kit Y719F/Y719F mutation might rescue azoospermia. We found that Kit V558Δ;Y719F/Y719F mice recapitulated the testis phenotype of Kit Y719F/Y719F mice. Matings with multiple WT females over more than 6 mo did not produce offspring, testicular volume was reduced, and testis cross-sections revealed empty tubules (Fig. 3D) . As was the case with survival, increasing the oncogenic dose in Kit V558Δ;Y719F/V558Δ;Y719F mice was not sufficient to compensate for the loss of KIT Y719 , indicating the need for at least one Y719 phosphorylation site for spermatogenesis. KIT is also known to have roles in hematopoiesis and mast cell development, and Kit mutant mice often present with a blood and/or mast cell phenotype. Skin mast cell numbers are increased in Kit V558Δ mice, while Kit V558Δ;T669I/+ mice develop mast cell hyperplasia and microcytic erythrocytosis (10, 11) . Nevertheless, in this study, the Kit V558Δ;Y719F/Y719F mice had normal peripheral blood and skin mast cell levels.
Even though Kit V558Δ is a potent oncogene and Kit Y719F only affects PI3K activation in mice, we cannot exclude the possibility that when both Kit V558Δ and Kit Y719F mutations reside on the same allele, the protein does not fold properly, thereby inactivating KIT (10, 24) . However, since Kit V558Δ;Y719F/Y719F mice have normal ICCs and pigmentation, it is likely that KIT is functional. Given that Kit-null is perinatal lethal (27) , the strongest in vivo evidence that this combination does not cause any severe KIT functional defects is our ability to derive viable adult mice homozygous for the Kit V558Δ;Y719F allele. To confirm that the KIT kinase is functional in the Kit V558Δ;Y719F mutation, we performed an in vitro kinase assay using cells expressing full-length KIT mutants. At baseline, without the addition of KIT ligand (KitL), KIT V558Δ;Y719F kinase activity was significantly higher than WT KIT activity and similar to that of the KIT V558Δ mutant (Fig. 3E ). Both mutants were hypersensitive to increasing doses of KitL compared with WT KIT.
To further confirm that KIT V558Δ;Y719F is functional, and to assess whether it is capable of canonical transphosphorylation, we transfected Kit constructs containing the WT, V558Δ, or V558Δ; Y719F mutations into 293T cells and measured KIT autophosphorylation by detection of specific KIT phosphotyrosine residues. The WT KIT receptor showed weak Y719 phosphorylation and barely detectable Y567/9 phosphorylation, similar to empty vector (Fig. 3F) , consistent with the absence of KitL. The weak phosphorylation of Y719 was most likely due to KIT overexpression leading to random dimerization of receptors. In contrast, the KIT V558Δ mutant had a net increase in both Y719 and Y567/9 phosphorylation, in accordance with its constitutive kinase activity. As expected, the KIT V558Δ;Y719F mutant lacked Y719 phosphorylation, but exhibited levels of Y567 and Y569 phosphorylation comparable to those of the KIT V558Δ mutant (Fig. 3F) mice is not due to a defect of the double-mutant KIT kinase, but rather must be explained by the lack of KIT pY719 signaling.
Response to Pharmacologic Inhibition of PI3K and MAPK in Kit V558Δ/+ Mice. Because PI3K signaling from KIT was required for GIST formation, we investigated whether selective pharmacologic inhibition of PI3K was effective against established tumors in Kit V558Δ/+ mice. We first tested the broadly acting dual PI3K/ mTOR inhibitor voxtalisib (XL765). Tumor lysates from mice treated for 6 h showed decreased PI3K signaling, manifested by reductions in pAKT, pS6, and p4EBP1 (Fig. 4A) . KIT and STAT3 phosphorylation were not affected, but, surprisingly, MAPK phosphorylation was increased. Seven days of treatment reduced tumor cell proliferation by 70% (Fig. 4B) , although the histological response was minimal (Fig. 4C, c) . To counteract MAPK activation by voxtalisib, we sought to use a MAPK inhibitor. The MEK inhibitor PD-325901 inhibited MAPK signaling without affecting PI3K and STAT signaling, but did not alter tumor proliferation (Fig. 4 B and D) . Treatment with voxtalisib and PD325901 for 6 h reduced both PI3K and MAPK signaling, as well as phospho-STAT3 signaling (Fig. 4E) . However, toxicity during 7 d of therapy required dosage reductions of both drugs to 5 mg/kg. Notably, low-dose voxtalisib and PD325901 therapy reduced tumor cell proliferation to a comparable degree as high-dose voxtalisib monotherapy (Fig. 4B) , although the histological response was minimal (Fig. 4C, d) . Taken together, these results indicate that targeting PI3K with the dual PI3K/mTOR inhibitor voxtalisib reduces tumor cell proliferation, but up-regulation of MAPK signaling might limit its efficacy.
The MAPK activation with voxtalisib therapy likely results from a feedback loop due to mTOR inhibition (28) . Therefore, to avoid MAPK activation, we next assessed the pan-class I PI3K selective inhibitor pilaralisib (XL147), which does not inhibit mTOR and thus more closely resembles the genetic abrogation of PI3K signaling from KIT. Tumor lysates from Kit 4 h with pilaralisib showed decreased PI3K signaling with reduced pAKT, pS6, and p4EBP1 (Fig. 5A) . In contrast, phosphorylated KIT, STAT3, and MAPK were unaffected (Fig. 5 A and B) . IHC of tumors following 7 d of pilaralisib treatment revealed a lack of phosphorylated S6, no effect on MAPK1/3 or STAT3 activation (Fig. 5C) , and reduced proliferation, yet only a minimal histological response (Fig. 4 B and C, e) .
Because Kit V558Δ;Y567F/Y567F tumors have less MAPK signaling and are smaller than Kit V558Δ/+ tumors, we reasoned that pilaralisib might be more effective if combined with a MAPK inhibitor. Thus, we treated Kit V558Δ/+ mice with the MEK inhibitor PD-325901 in addition to pilaralisib. After 6 h of treatment, PI3K and MAPK signaling were reduced, as was STAT3 signaling (Fig. 5D) . Unfortunately, combination therapy was too toxic over 7 d of therapy.
Since voxtalisib and pilaralisib in combination with PD-325901 were not well tolerated, we evaluated other PI3K and MEK inhibitors. Alpelisib is a potent PIK3CA (PI3K-α) inhibitor, with minimal effects on PIK3CB (PI3K-β), PIK3CD (PI3K-δ), or PIK3CG (PI3K-γ). Kit V558Δ/+ mice treated for 7 d with alpelisib had decreased PI3K signaling with reduced pAKT, pS6, and p4EBP1, while KIT, MAPK, and STAT3 activation were unchanged (Fig. 6A ). Mice treated for 7 d with the ATP noncompetitive MEK inhibitor binimetinib had less pMAPK1/3 (Fig. 6B) . pSTAT3 was also reduced, but PI3K signaling was unaltered. The combination of alpelisib and binimetinib was well tolerated and reduced PI3K pathway activation, pMAPK1/3, and pSTAT3 (Fig.  6C) . Furthermore, tumor cell proliferation was reduced by 75%, while the histological response was slightly improved (Fig. 4 B  and C, f) .
Imatinib-Resistant Kit V558Δ;T669I/+ Tumors Respond to Dual PI3K and MEK Inhibition. Since alpelisib and binimetinib were found to target two major signaling pathways downstream of KIT and to lack toxicity in Kit V558Δ/+ mice, we evaluated whether they could be used in combination to overcome imatinib resistance. For this purpose, imatinib-resistant Kit V558Δ;T669I/+ mice (11) were treated for 7 d with alpelisib and binimetinib. Both PI3K and MAPK signaling were reduced, as was tumor cell proliferation ( Fig. 7 A  and B) . Furthermore, the histological response was increased (Fig. 7C) . Thus, targeting downstream components of KIT signaling was also effective in the setting of imatinib resistance. mice that are homozygous for the Y567F mutation, to ensure that any signal that normally emanates from phospho-Y567 is abrogated. SFK activation was dramatically impaired in GIST of the Kit V558Δ;Y567F/Y567F mice compared with the Kit V558Δ/+ mice. This is consistent with an important role for SFKs in KITmediated activation of the RAS/MAPK pathway (15) . In addition, we observed a partial reduction in STAT3 signaling in tumors of Kit V558Δ;Y567F/Y567F mice (29) . In mast cell/myeloid cell transformation by oncogenic Kit, Y567F mutation accelerated tumorigenesis, presumably due to inhibited activation of SHIP1, A B C D Fig. 5 . Inhibition of PI3K resulted in a significant reduction in GIST proliferation. Kit V558Δ/+ mice (n = 4/group) were treated for 4 h (A) with pilaralisib (100 mg/kg) alone, (B) with PD-325901 (15 mg/kg) alone, and (D) with both pilaralisib (100 mg/kg) and PD-325901 (15 mg/kg) and analyzed by immunoblotting. (B) Comparison of the level of activation of phospho-MAPK1/3 in GIST from mice treated with voxtalisib and pilaralisib alone or in combination with PD-325901. The level of activation of phospho-MAPK1/3 was determined by densitometry analysis of the respective bands from Western blots and measured as the ratio of phospho/total for each protein compared with control. The scale is arbitrary units (intensity of gray shading). (C) Representative results of IHC analysis of GIST after long-term (7 d) treatment of Kit V558Δ/+ mice with vehicle (control), pilaralisib, or imatinib. As a positive control for IHC, imatinib downregulated all three signaling readouts-p-MAPK, pS6, and p-STAT3-as reported previously (11) . Antibodies used are specific for pS6 (a-c), p-MAPK1/3 (d-f), and p-STAT3 (g-i) on 5-μm sections of GISTs. Tumor sections from the different treatment groups (n ≥3 animals each) were placed next to each other on the same microscope slide to enable cross-comparison of staining intensities (40× objective).
Discussion
a hematopoietic-specific negative regulator of PI3K (14, 17, 30) . In contrast, in Kit V558Δ;Y567F/Y567F mice, the Y567F mutation diminished tumorigenesis, indicating that KIT pY567 is a positive regulator of tumorigenesis in GIST. Since a mild hematopoietic pro-B/pro T-cell phenotype in KIT Y567F/Y567F mutant mice becomes apparent after age 8 mo, biochemical analysis of tumor tissue was performed in tumors from 3-to 4-mo-old mice (20, 22) . Importantly, our results provide in vivo evidence that the direct activation of the PI3K-pathway via KIT Y719 is required for GIST tumorigenesis. The KIT Y719 phosphorylation site also has been postulated to be of importance in myeloproliferative disease induced by the kinase domain mutation KIT D814V (human KIT D816V ), based on experiments with chimeric proteins consisting of the extracellular domain of human M-CSFR and the intracellular domain of murine KIT (18, 31) . We considered the possibility of defective ICC development in Kit V558Δ;Y719F/Y719F mice, which would readily explain the absence of hyperplasia and tumor development, as ICCs or their progenitors are the presumed cells of origin of GIST (32) . However, ICCs developed normally and stained positive for KIT. In addition, the kinase activity of the KIT V558Δ;Y719F protein was not impaired, strengthening the idea that disruption of PI3K signaling is responsible for the lack of tumor development. The mutant KIT alleles were expressed under the control of the endogenous Kit transcription machinery and thus expressed continuously during ICC development; that is, the experiments did not distinguish whether the phenotypes derived were due to a failure in tumor initiation or a failure in maintaining an oncogenic state. Also, Kit V558Δ;Y719F/Y719F mice lacked the PI3K-binding site in all KIT-expressing cells starting at fertilization. Thus, we cannot rule out that the absence of tumorigenesis in our model could be the result of a defect in tumor initiation.
In addition, it is possible that proteins other than PI3K-family members are being recruited to the phospho-KIT Y719 site and are necessary for transformation. Nevertheless, pharmacologic inhibitors of the PI3K pathway in tumor-bearing Kit V558Δ/+ mice, including the dual PI3K/mTOR inhibitor voxtalisib, the pan-PI3K inhibitor pilaralisib, and the PI3K-alpha-restricted inhibitor alpelisib, each diminished tumor proliferation, indicating that PI3 kinase makes a major contribution to tumor cell proliferation in established GIST. The presumed selectivity of these inhibitors for PI3K was generally confirmed in our mice, since phosphorylation of S6 kinase and 4EBP1 were inhibited, while MAPK and STAT3 activation were unaffected. The dual PI3K/mTOR inhibitor voxtalisib increased MAPK activation in GIST. This is consistent with reports that mTORC1 inhibition promotes MAPK activation in a mouse model of prostate cancer and in patients with metastatic disease subjected to mTOR inhibition therapy (28) . The feedback A B C activation of MAPK with voxtalisib provided a rationale for using an MEK inhibitor in combination with a PI3K inhibitor.
In contrast to mice carrying the Kit V558Δ;Y719F/Y719F double mutation, mice carrying a Kit V558Δ;Y567F/Y567F double mutation developed GIST, although tumor development was attenuated and the animals had an extended lifespan. In these animals, PI3K signaling was not affected, but SFK pathway activation was strongly diminished, and phospho-MAPK1/3 and phospho-STAT3 were reduced as well. In agreement with those observations, treatment of Kit V558Δ/+ mice with the MEK inhibitors PD-325901 or binimetinib diminished MAPK1/3 and STAT3 phosphorylation/activation. These findings indicate a requirement for the direct engagement of distinct pathways by KIT for full tumor growth. Thus, dual inhibition of both the PI3K and MAPK branches in oncogenic KIT signaling was pursued. Whereas combination treatment with either voxtalisib plus PD-325901 or pilaralisib plus PD-325901 was too toxic, combination treatment with the PI3K-alpha inhibitor alpelisib and the MAPK inhibitor binimetinib was tolerated and shows promise for use in patients with GIST, particularly those with imatinibresistant GIST, as demonstrated in imatinib-resistant gatekeeper Kit V558Δ;T669I/+ mice. PI3K inhibitors alone and in combination with imatinib have shown antitumor effects in GIST xenograft models; however, the most common imatinib-resistant GIST mutations (KIT exons 11-13 and 11-14) have not been tested (33, 34) . Targeting of the PI3K pathway with the AKT inhibitor MK-2206 has been shown to increase imatinib efficacy in cell culture and in xenografts with imatinib-sensitive and -resistant GIST cell lines (35) . Our studies with immunocompetent mice carrying either the Kit V558Δ or the common KIT imatinib-resistant gatekeeper mutation strengthen our argument that the combination of PI3K and MEK inhibition could be beneficial for treating patients with imatinibresistant GIST.
In summary, our results suggest that a detailed analysis of distinct oncogenic signaling pathways mediated by oncogenic tyrosine kinases in specific cellular contexts may lead to new and improved treatment strategies.
Materials and Methods
Generation of Mouse Strains. The V558Δ mutation was introduced by sitedirected mutagenesis into a 2.1-kb EcoRI/MluI fragment across Kit exons 9-11 from a 129/SvJ mouse library (24) serving as the 5′ homology arm of the targeting vector. For the Kit V558Δ;Y567F allele, the Y567F mutation was introduced into the same 5′ arm for homologous recombination (HR) (Fig. S1) and Kit V558Δ;Y719F projects, respectively. Four ES cell clones carried both the V558Δ mutation and the nearby Y567F mutation, and two clones carried both the V558Δ mutation and the distant Y719F mutation, respectively, as assessed by sequencing, and showed a normal karyotype. C57BL/6J blastocyst injections of two of these clones each gave rise to 19/21 high-grade chimeras (>90% agouti coat color), one each of which gave germ line transmission of the double mutations. After crossing to C57BL/6J mice, in all agouti F1 animals heterozygous for the NEO allele, the presence of the V558Δ;Y56F and V558Δ;Y719F mutations, and the integrity of both loxP sites was confirmed by sequencing. To remove the floxed NEO cassette, F1 Kit V558Δ;Y567F-NEO/+ and Kit V558Δ;Y719F-NEO/+ males were bred to B6.FVBTg(EIIa-cre) C5379Lmgd/J females (The Jackson Laboratory).
Genotyping PCR was performed across the original intron 11 MluI site, which was replaced by a 134-bp loxP scar in the case of the targeted alleles. Of the two resulting fragments (WT allele, 643 bp; targeted allele, 777 bp), the longer one was isolated by gel purification, and the integrity of the V558Δ mutation (and in case of the Kit V558Δ;Y567F allele, of the adjacent Y567F , resulting in complementation of the two fragments of β-gal and formation of a functional enzyme. β-gal activity was then quantitatively detected using the chemiluminescent substrate in the PathHunter Kit.
Western Blot Analysis. Tumor lysates were prepared as described previously (13) with the following modifications. Snap-frozen tumor was first homogenized in a PowerGen 1000 homogenizer (Thermo Fisher Scientific) and then incubated on ice for 30 min. Lysates were cleared by centrifugation at 4°C for 30 min and then fractionated by SDS/PAGE. Protein extracts were prepared from tumors of several mice to assess individual variability in the response to drugs. Proteins were visualized by Western blot analysis after incubation with appropriate antibodies. Phospho-KIT (Tyr719), KIT, Phosphop44/42 MAPK (Thr202/Tyr204), p44/42 MAPKinase, phospho-S6 protein (Ser235/236), S6 protein, phospho-AKT (Ser473), AKT, phospho-STAT3 (Tyr705), STAT3, phospho-STAT5 (Tyr694), STAT5, phospho-SRC family (Tyr416), and SRC were obtained from Cell Signaling Technology. Phospho-KIT (Tyr568 + Tyr569) was obtained from Abcam.
Drug Treatment in Mice. Mice were maintained in a specific pathogen-free animal facility and used in accordance with an institutional approved protocol. Voxtalisib (XL765) and pilaralisib (XL147) were provided by Exelixis. Voxtalisib was suspended at 2 mg/mL in water/10 mM HCl. For the 6-h treatment, voxtalisib was administered once at 30 mg/kg by gavage. For the 7-d treatment, it was administered at 20 mg/kg by gavage twice a day (30 mg/kg was toxic). PD325901 was administered by gavage, once at 5 or 15 mg/kg for the 6-h treatment and once a day at 15 mg/kg for the 7-d treatment. For combination treatment with voxtalisib and PD325901, the dose had to be reduced to 5 mg/kg each and administered only once daily. Pilaralisib was solubilized in water, sonicated and administered at 100 mg/kg by gavage within 60min of formulation. It was administered once for the 4-h treatment, and once a day for the 7-d treatment. For combination treatment, pilaralisib and PD325901 were administered daily at 100 mg/kg and 15 mg/kg, respectively. Alpelisib (37) and binimetinib (38) were suspended at 4 mg/mL in 0.5% Tween 80 and 1% carboxymethyl cellulose in water. Alpelisib was administered at 20 mg/kg (Western blots), 40 mg/kg (Ki-67 and trichrome), or 65 (Ki-67) mg/kg by gavage once daily for 7 d. Binimetinib was administered at 3.5 mg/kg (Western blots) or 10 mg/kg (Ki-67 and trichrome) by gavage twice daily for 7 d. For combination treatment, alpelisib and binimetinib were administered for 7 d at 20 mg/kg (once daily) and 3.5 mg/kg (twice daily), respectively (Western blots) or at 40 mg/kg (once daily) and 10 mg/kg (twice daily), respectively (Ki-67 and trichrome). Imatinib mesylate (Novartis) was suspended in water and injected i.p. twice daily at 45 mg/kg. Sunitinib malate (LC Laboratories) was solubilized freshly in 30% Cremophor EL (Sigma-Aldrich), 30% polyethylene glycol 400, 10% ethanol, and 10% glucose every 4 d and was administered at 40 mg/kg once daily by gavage.
